Differences in Occurrence, Risk Factors and Severity of Early-onset Atopic Dermatitis among Preterm and Term Children

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 453 KB, PDF-dokument

This prospective birth cohort followed 150 preterm and 300 term newborns during the first year of life to assess possible differences in risk factors, age at onset, anatomical location, and severity of atopic der-matitis. Atopic dermatitis was diagnosed clinically, and severity was assessed using Eczema Area Severity Index (EASI). DNA was analysed for filaggrin gene mutations. Parents were asked about environmental exposures and emollient use. Atopic dermatitis during the first year of life was observed in 21.2% of children and was more common in term children compared with preterm children (26.7% vs 11.7%, p < 0.001), with lower age of onset (4 vs 6 months, p < 0.05) and more severe disease at onset (EASI: 4.8 vs 0.4, p < 0.0005). Environmental risk factors for atopic dermatitis were essentially similar for preterm and term born children, apart from winter and autumn births. Filaggrin gene mutations were less common in preterm than term children (4.1% vs 9.2%, p = 0.06).

OriginalsprogEngelsk
Artikelnummeradv00737
TidsskriftActa Dermato-Venereologica
Vol/bind102
Antal sider7
ISSN0001-5555
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
We thank all families for their participation in the BABY cohort. We thank all staff members at Rigshospitalet and Nordsjællands Hospital who contributed to this study. The study received financial support from The Leo Foundation, The Lundbeck Foundation, The Novo Nordisk Foundation, Pfizer, Kgl. Hofbundtmager Aage Bangs Foundation, Savvaerksejer Jeppe Juhl og Hustru Ovita Juhls Mindelegat and The Herlev and Gentofte Hospital Research Foundation. Conflicts of interest: JPT reports grants from The Leo Foundation, The Novo Nordisk Foundation, Pfizer, The Lundbeck Foundation and grants from Savværksejer Jeppe Juhl og hustru Ovita Juhls Mindelegat, during the conduct of the study. JPT has been an advisor, investigator and speaker for Abbvie, Regeneron, Pfizer, Sanofi-Genzyme, LEO Pharma, and Eli Lilly & Co. LS reports personal fees from Abbvie, Eli Lilly, Novatis, Sanofi, Celegen LEO Pharma, and Almirall, outside the submitted work. LS reports non-financial support from Abbvie, Sanofi, Janssen and grants from Novartis, Janssen and Sanofi. TG, AH, MRR, reports grants from Herlev and Gentofte Hospital Research Foundation and Kgl. Hoftbundtmager Aage Bangs foundation during the conduct of the study. AH reports personal fees from LEO Pharma and Coloplast A/S outside the submitted work. MHK reports grants from Herlev and Gentofte Hospital Research Foundation, during the conduct of the study. NHR reports grant from the Novo Nordisk Foundation and Herlev and Gentofte Hospital Research Foundation, during the conduct of the study.

Publisher Copyright:
© 2022, Medical Journals/Acta D-V. All rights reserved.

ID: 325378812